Assorted News from Last Week: Kazia Therapeutics Limited, an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to Kazia’s paxalisib for the treatment of atypical rhabdoid / teratoid tumors (AT/RT), a rare and highly-aggressive childhood brain cancer. Bridge therapy ahead of autologous stem cell transplantation (ASCT) consolidation may benefit certain high-risk neuroblastoma patients with residual disease following induction regimens, according to a multicenter retrospective study. Novartis announced the FDA has granted accelerated approval to the BRAF inhibitor dabrafenib (Tafinlar) combined with the MEK inhibitor trametinib […]
Read more